
RxSight (RXST) Stock Forecast & Price Target
RxSight (RXST) Analyst Ratings
Bulls say
RxSight Inc. has demonstrated positive momentum, with a revenue beat in 3Q25 and a raised mid-point guidance, reflecting the company’s commitment to enhancing its Light Adjustable Lens (LAL) volumes through targeted engagement initiatives. The anticipation of sustained double-digit growth is supported by a growing installed base of Light Delivery Devices (LDD) and increased utilization, which positions the company favorably in the medical technology landscape. Furthermore, the management’s projection of improved gross margins, now estimated between 76-77%, underscores the potential for enhanced profitability amid strategic operational focus.
Bears say
RxSight Inc. is experiencing a decline in both monthly utilization rates and revenue, with a reported 14% year-over-year decrease, indicating potential challenges in customer adoption and demand for its light adjustable lenses (LALs). In the second quarter of 2025, the company placed only 25 light delivery devices (LDDs), which represents a substantial 68% drop year-over-year and a 38% decrease quarter-over-quarter, significantly underperforming expectations. Additionally, risks related to limited market adoption due to the necessity of additional capital equipment, disappointing commercial execution, and the potential for increased competition in the intraocular lens market further contribute to a negative outlook on RxSight's stock.
This aggregate rating is based on analysts' research of RxSight and is not a guaranteed prediction by Public.com or investment advice.
RxSight (RXST) Analyst Forecast & Price Prediction
Start investing in RxSight (RXST)
Order type
Buy in
Order amount
Est. shares
0 shares